Member Info for LovableLumax

I no longer work in the city so aren’t in ‘the know’ as it were. There will be candidates who will likely need to lean on the science bods at Avacta and elsewhere but will have a lot more commercial nouse. Taking a £50-£100m market cap co to a £1bn+ is a different skill set which is why it’s not for everyone. AS has no doubt done very well but it seems obvious to me he’s not the man to take Avacta to the next level and beyond. Or at least lay the foundations to get to the next level as it’ll increase value and get on more of the radars we want. I really don’t think AS is thought of a serious player in the city and although the science and platforms are all important an experienced and commercial CEO is needed to create and sustain value at a higher end.

A good example is the founder of Abcam, Jonathan Milner who took it from £25m or so to £500m or so before stepping aside as he’d taken it as far as he could.

Would CC want to be CEO, does she has the experience? She’s based in the US I believe so that’s an issue. CC could do a superb job in current role and support a CEO who’s able to take us to the next few levels. It’s AS’ baby but sadly if he doesn’t realise he should move aside for the greater good it’ll have to be forced on him. New CEO of course integral in appointing a new CFO. I’d hope the chairman would lean on AS to do the right thing.

First and foremost regain momentum and hopefully AACR will do so and then regain trust and credibility with a new CEO and new approach especially managing comms, creating and sustaining shareholder value and ensure the current plan re 6000 the best route to market and I suspect the new approach will be.

chairman is meant to manage the bod and protect shareholders. he's failed miserably, no question. ceo hasn't a commercial bone in his body and given we're aim listed, have few analysts following us with a largely retail base and have quarterly conversions the comms is so bad it's negligent. an absolute **** show and a lot of it seems unnecessary. changes needed imo, defo ceo and cfo have to go and the chairman needs to either pull his finger out or leave too. a lot of disruption but a new ceo needed and that should be the priority and i assume do so after aacr

According to the chairman the beauty of AVA6000 is that is allows dox to target the stroma which many anthracyclines are unable to do.

Copied and pasted the below -

The tumor microenvironment is a dynamic composite of cells broadly categorized as multiple components of no-stroma and stroma cells, where tumor cells thrive. Stroma cells promote tumor growth, invasion, and metastasis by secreting multiple cytokines, chemokines and other growth factors, et al.

AVA6000, dox and other anthracyclines will be excreted and whether the TME at different rates depending on the patient. That’s obvious. One thing is for sure the biopsies showed the the mechanism of action working as it did preclinical with lots more dox in the tumour than in blood which is why no MTS was found.

BNN Breaking is a news website based in Hong Kong launched in 2022 by Indian-American entrepreneur Gurbaksh Chahal. It has been criticised for posting a number of misleading and inaccurate news stories, potentially using AI-driven content aggregation.

Funny JWBellamy keep asking the same question even though he's been told the BOD has loads of options so the buys were for perception more than anything. JWB, again, how large is your short? Given the frequency of your posts surely it's large.

Funny JWBellamy keep asking the same question even though he's been told the BOD has loads of options so the buys were for perception more than anything. JWB, again, how large is your short? Given the frequency of your posts surely it's large?

Perhaps we'll hear more on the 3 weekly read-out.

I think it's good to see plenty of sellers who are indeed flipping their new shares for 5% or so. Clear as many of them down here now and when positive RNSs land we are able to move on up. There'll always be profit taking but for me get rid of as many as possible now is best.

JWB I hold here and my average around 90p so I am on paper down a shed load although my investment decision had nowt to do with Myles' investment and nor should anyone's.

Are you still short here?

JWB with the incessant posting I hope your short is a large as very odd otherwise

The II shares are already in circluation so I assume they have fewer than 9m or so (3%)

Just look back at the science day deck and you will see what the targets were and what was achieved.

Agreed it's not a good look but if CFO buys shares at 50p when he could have a bunch at 10p it looks financially illiterate and I suspect AS did a modest number for perception. That said I think both should be shown the door and I suspect if there are numbers for this it makes sense to do so after AACR, results RNS and CLN recalculation

Again, they have options although good to see Christina Coughlin take a decent number

You keep asking the same question. CEO and CFO have options, check out the remuneration report in the last annual report.

The reason it is running at a loss is because the DX division includes all of the existing Avacta staff. If they integrated the acquisiitions and excluded Avacta staff it would be profitable and I assume that's how it will be sold

His options are ridiculous and need to be reset..

If we can sell DX for even £20m (huge loss) but ideally £25m-£30m we are laughing and will hopefully look back on this period as a very harsh lesson.

But limited to existing shareholders. Makes sense. So if approved on 18 March they will have over £40m and cash for 2 years.